Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSICART
2024-517030-17-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bosentan in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Failure-free survival at week 52. Planned start Aug 2025; status: authorised.
02
Drugs
bosentan
03
Conditions
giant cell arteritis (GCA)polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2024-517030-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517030-17-00.